1. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Issue 12 (December 2016) Authors: Frías, Juan P; Guja, Cristian; Hardy, Elise; Ahmed, Azazuddin; Dong, Fang; Öhman, Peter; Jabbour, Serge A Journal: Lancet Issue: Volume 4:Issue 12(2016) Page Start: 1004 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗